Joshua A Hill1, Michael J Boeckh2, Ruth Hall Sedlak3, Keith R Jerome4, Danielle M Zerr5. 1. Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, United States; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States. Electronic address: joshuaah@uw.edu. 2. Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, United States; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States. 3. Department of Laboratory Medicine, University of Washington, Seattle, WA, United States. 4. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Department of Laboratory Medicine, University of Washington, Seattle, WA, United States. 5. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Seattle Children's Research Institute, Seattle, WA, United States.
Abstract
BACKGROUND: Human herpesvirus 6 (HHV-6) is an opportunistic pathogen after hematopoietic cell transplantation (HCT) that is associated with central nervous system (CNS) dysfunction. OBJECTIVES: The aim of this study was to determine the frequency and significance of HHV-6 DNA detection in cerebrospinal fluid (CSF) after HCT. STUDY DESIGN: We identified patients with HHV-6 DNA in CSF using quantitative PCR. Patients with neurologic symptoms and HHV-6 DNA in CSF without identification of an alternative etiology were categorized as having HHV-6 CNS dysfunction. RESULTS: Among 3902 allogeneic HCT recipients from 1998 to 2012, 51 of 124 tested patients had HHV-6 DNA in CSF; 37 met criteria for HHV-6 CNS dysfunction and 14 (27%) did not. Patients with an alternative diagnosis had longer time to HHV-6 detection and lower viral load in CSF. Six patients without HHV-6 CNS dysfunction were not treated and had no morbidity attributable to HHV-6. Kaplan-Meier analysis demonstrated poor overall survival among all patients. Variables associated with higher all-cause mortality in a multivariable Cox model included alternative diagnosis (adjusted hazard ratio [aHR], 8.4; 95% CI, 1.7-40.9; P = 0.009) and higher peak plasma viral load (log(10) scale) (aHR, 1.4; 95% CI, 1.1-1.9; P = 0.01). CONCLUSION: We identified a number of allogeneic HCT recipients with HHV-6 DNA in CSF who did not meet criteria for HHV-6 CNS dysfunction. All patients had poor survival. Whether CSF HHV-6 DNA detection in patients without associated CNS dysfunction independently contributes to mortality and warrants treatment is unclear; management of these patients warrants further investigation.
BACKGROUND:Human herpesvirus 6 (HHV-6) is an opportunistic pathogen after hematopoietic cell transplantation (HCT) that is associated with central nervous system (CNS) dysfunction. OBJECTIVES: The aim of this study was to determine the frequency and significance of HHV-6 DNA detection in cerebrospinal fluid (CSF) after HCT. STUDY DESIGN: We identified patients with HHV-6 DNA in CSF using quantitative PCR. Patients with neurologic symptoms and HHV-6 DNA in CSF without identification of an alternative etiology were categorized as having HHV-6 CNS dysfunction. RESULTS: Among 3902 allogeneic HCT recipients from 1998 to 2012, 51 of 124 tested patients had HHV-6 DNA in CSF; 37 met criteria for HHV-6 CNS dysfunction and 14 (27%) did not. Patients with an alternative diagnosis had longer time to HHV-6 detection and lower viral load in CSF. Six patients without HHV-6 CNS dysfunction were not treated and had no morbidity attributable to HHV-6. Kaplan-Meier analysis demonstrated poor overall survival among all patients. Variables associated with higher all-cause mortality in a multivariable Cox model included alternative diagnosis (adjusted hazard ratio [aHR], 8.4; 95% CI, 1.7-40.9; P = 0.009) and higher peak plasma viral load (log(10) scale) (aHR, 1.4; 95% CI, 1.1-1.9; P = 0.01). CONCLUSION: We identified a number of allogeneic HCT recipients with HHV-6 DNA in CSF who did not meet criteria for HHV-6 CNS dysfunction. All patients had poor survival. Whether CSF HHV-6 DNA detection in patients without associated CNS dysfunction independently contributes to mortality and warrants treatment is unclear; management of these patients warrants further investigation.
Authors: Julie Fotheringham; Nahid Akhyani; Alexander Vortmeyer; Donatella Donati; Elizabeth Williams; Unsong Oh; Michael Bishop; John Barrett; Juan Gea-Banacloche; Steven Jacobson Journal: J Infect Dis Date: 2006-12-27 Impact factor: 5.226
Authors: Danielle M Zerr; Jesse R Fann; David Breiger; Michael Boeckh; Amanda L Adler; Hu Xie; Colleen Delaney; Meei-Li Huang; Lawrence Corey; Wendy M Leisenring Journal: Blood Date: 2011-03-09 Impact factor: 22.113
Authors: Ruth Hall Sedlak; Linda Cook; Meei-Li Huang; Amalia Magaret; Danielle M Zerr; Michael Boeckh; Keith R Jerome Journal: Clin Chem Date: 2014-03-04 Impact factor: 8.327
Authors: W W Seeley; F M Marty; T M Holmes; K Upchurch; R J Soiffer; J H Antin; L R Baden; E B Bromfield Journal: Neurology Date: 2007-07-10 Impact factor: 9.910
Authors: Joshua A Hill; Sophia Koo; Belisa B Guzman Suarez; Vincent T Ho; Corey Cutler; John Koreth; Philippe Armand; Edwin P Alyea; Lindsey R Baden; Joseph H Antin; Robert J Soiffer; Francisco M Marty Journal: Biol Blood Marrow Transplant Date: 2012-05-04 Impact factor: 5.742
Authors: Lena E Winestone; Rajesh Punn; John S Tamaresis; Julia Buckingham; Benjamin A Pinsky; Jesse J Waggoner; Sandhya Kharbanda Journal: Pediatr Transplant Date: 2017-11-27
Authors: Joshua A Hill; Ruth Hall Sedlak; Danielle M Zerr; Meei-Li Huang; Cecilia Yeung; David Myerson; Keith R Jerome; Michael J Boeckh Journal: Biol Blood Marrow Transplant Date: 2014-09-22 Impact factor: 5.742
Authors: Joshua A Hill; Minako Ikoma; Danielle M Zerr; Ryan S Basom; Vikas Peddu; Meei-Li Huang; Ruth Hall Sedlak; Keith R Jerome; Michael Boeckh; Serge Barcy Journal: J Virol Date: 2019-01-17 Impact factor: 5.103